{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000087","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.754066+00:00","generated_at":"2026-06-04T00:05:55.020557+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CFO Melissa Epperly resigns; President Cam Gallagher named interim CFO","bullets":["Melissa Epperly resigned as CFO, treasurer, principal financial and accounting officer effective April 5, 2024.","President Cam Gallagher appointed interim CFO, treasurer and principal financial officer; VP Finance Vincent Vultaggio named interim principal accounting officer.","Chief Business Officer Kyle Rasbach will oversee Investor Relations on an interim basis.","Company is conducting a search for a new permanent CFO.","Epperly eligible for severance benefits under her amended employment agreement, subject to execution of a release."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000087","json":"https://secwatch.observer/filing/0001725160-24-000087.json","markdown":"https://secwatch.observer/filing/0001725160-24-000087.md","text":"https://secwatch.observer/filing/0001725160-24-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000087/0001725160-24-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000087/zntl-20240405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:05:55.020557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d9580cb51","claim":"Vincent Vultaggio was appointed as interim principal accounting officer at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000087/0001725160-24-000087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}